14.19
-0.63(-4.25%)
Currency In USD
| Previous Close | 14.82 |
| Open | 14.65 |
| Day High | 14.8 |
| Day Low | 14.17 |
| 52-Week High | 33.33 |
| 52-Week Low | 10.57 |
| Volume | 1.52M |
| Average Volume | 1.74M |
| Market Cap | 2.07B |
| PE | -5.05 |
| EPS | -2.81 |
| Moving Average 50 Days | 14.58 |
| Moving Average 200 Days | 16.9 |
| Change | -0.63 |
If you invested $1000 in Denali Therapeutics Inc. (DNLI) since IPO date, it would be worth $661.54 as of September 13, 2025 at a share price of $14.19. Whereas If you bought $1000 worth of Denali Therapeutics Inc. (DNLI) shares 5 years ago, it would be worth $393.4 as of September 13, 2025 at a share price of $14.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
GlobeNewswire Inc.
Jul 07, 2025 12:00 PM GMT
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approvalTividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brainTividenofusp alfa leads company’s broader
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
GlobeNewswire Inc.
Apr 02, 2025 12:00 PM GMT
Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026Alignment through recent interactions with CDER on path to accelerated approval and conversion to full appr
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
GlobeNewswire Inc.
Feb 06, 2025 4:42 PM GMT
Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued improvement in hearing, cognition and adaptive behaviorLong-term safety data with median follow-up of two yea